Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Robert Burns
HC
Robert Burns
H.C. Wainwright
Wall Street Analyst
★☆☆☆☆
#2385
on 13Foresight · ranked by our own returns
45%
Success Rate
-4.5%
Average Return
21 of 47 calls profitable · -10.2% vs benchmark
📈 Across the calls we could measure, roughly 45% of Robert Burns's ratings turned a profit when each position was held for 1 year — averaging -4.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

223 Buy 17 Hold 1 Sell
Robert's Stock Coverage 49 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
KPTI
Karyopharm Therapeutics
 Jun 18, 2026 BUY Strong Buy
+146.1% avg upside
18 analysts
$13.00
44.12% Upside
 ·
COGT
Cogent Biosciences
 Jun 18, 2026 BUY Strong Buy
+7.4% avg upside
26 analysts
$55.00
59.26% Upside
 +0.0%
ELTX
Elicio Therapeutics
 Jun 16, 2026 BUY Buy
+380.1% avg upside
11 analysts
$23.00
497.35% Upside
 ·
CRBU
Caribou Biosciences
 Jun 16, 2026 BUY Strong Buy
+581.8% avg upside
12 analysts
$11.00
570.76% Upside
 ·
NRIX
Nurix Therapeutics
 Jun 11, 2026 BUY Strong Buy
+76.3% avg upside
26 analysts
$32.00
82.41% Upside
 ·
TNGX
Tango Therapeutics
 Jun 10, 2026 BUY Strong Buy
+24.2% avg upside
14 analysts
$66.00
135.94% Upside
 +12.6%
FATE
Fate Therapeutics
 Jun 08, 2026 BUY Buy
+492.3% avg upside
31 analysts
$7.00
234.99% Upside
 ·
CGEM
Cullinan Management
 Jun 08, 2026 BUY Strong Buy
+125.7% avg upside
15 analysts
$30.00
99.66% Upside
 +8.7%
ADCT
ADC Therapeutics
 Jun 08, 2026 HOLD Buy
+450.4% avg upside
12 analysts
 — ·
ORIC
Oric Pharmaceuticals
 Jun 08, 2026 BUY Strong Buy
+180.1% avg upside
19 analysts
$25.00
194.55% Upside
 +9.8%
RADX
Radiopharm Theranostics Limited Sponsored ADR
 Jun 04, 2026 BUY Strong Buy
+312.0% avg upside
6 analysts
$16.00
259.50% Upside
 ·
AKTS
Aktis Oncology, Inc.
 Jun 03, 2026 BUY Strong Buy
+31.0% avg upside
8 analysts
$35.00
45.33% Upside
 ·
ZYME
Zymeworks
 Jun 03, 2026 BUY Strong Buy
+40.3% avg upside
25 analysts
$46.00
98.83% Upside
 -7.6%
RVMD
Revolution Medicines
 Jun 02, 2026 BUY Strong Buy
-12.2% avg upside
32 analysts
$195.00
19.70% Upside
 +4.3%
BCAX
Bicara Therapeutics Inc.
 Jun 01, 2026 BUY Strong Buy
+34.2% avg upside
14 analysts
$42.00
80.85% Upside
 +11.2%
CRDF
Cardiff Oncology
 Jun 01, 2026 HOLD Strong Buy
+736.8% avg upside
18 analysts
 — ·
CATX
Perspective Therapeutics
 Jun 01, 2026 BUY Strong Buy
+278.9% avg upside
22 analysts
$13.00
340.74% Upside
 -20.0%
BOLT
Bolt Biotherapeutics
 May 28, 2026 BUY Buy
+475.8% avg upside
7 analysts
$7.00
75.39% Upside
 -14.0%
RLAY
Relay Therapeutics
 May 26, 2026 BUY Strong Buy
+26.5% avg upside
19 analysts
$28.00
76.37% Upside
 +11.9%
NUVB
Nuvation Bio
 May 26, 2026 BUY Strong Buy
+132.2% avg upside
15 analysts
$17.00
205.80% Upside
 +13.7%
BDTX
Black Diamond Therapeutics
 May 22, 2026 BUY Strong Buy
+987.8% avg upside
12 analysts
$11.00
562.62% Upside
 ·
IMMX
Immix Biopharma
 May 22, 2026 BUY Strong Buy
+105.0% avg upside
8 analysts
$20.00
129.32% Upside
 +0.0%
AVBP
ArriVent BioPharma, Inc.
 May 12, 2026 BUY Strong Buy
+37.1% avg upside
15 analysts
$44.00
38.62% Upside
 +8.2%
ELVN
Enliven Therapeutics
 May 11, 2026 BUY Strong Buy
+7.2% avg upside
14 analysts
$56.00
24.17% Upside
 +9.8%
MGNX
MacroGenics
 May 07, 2026 HOLD Buy
+326.4% avg upside
25 analysts
 — +41.5%
EXEL
Exelixis
 May 07, 2026 BUY Strong Buy
-21.1% avg upside
33 analysts
$56.00
7.91% Upside
 +15.0%
BBOT
BridgeBio Oncology Therapeutics
 May 01, 2026 BUY Strong Buy
+231.7% avg upside
10 analysts
$29.00
283.69% Upside
 -8.5%
PRLD
Prelude Therapeutics
 Apr 27, 2026 BUY Buy
+151.3% avg upside
7 analysts
$8.00
85.11% Upside
 -0.9%
BNTX
BioNTech SE
 Apr 27, 2026 BUY Strong Buy
+50.5% avg upside
26 analysts
$130.00
43.09% Upside
 -10.9%
MOLN
Molecular Partners
 Apr 22, 2026 BUY Strong Buy
+161.4% avg upside
7 analysts
$13.00
240.27% Upside
 -3.2%
WHWK
Whitehawk Therapeutics
 Apr 21, 2026 HOLD Buy
+201.4% avg upside
12 analysts
 — +0.5%
ALLO
Allogene Therapeutics
 Apr 16, 2026 BUY Strong Buy
+662.8% avg upside
28 analysts
$11.00
449.99% Upside
 -19.8%
REPL
Replimune Group
 Apr 13, 2026 SELL Hold
+72.3% avg upside
13 analysts
 — -499.4%
ACET
Adicet Bio
 Mar 23, 2026 BUY Strong Buy
+212.8% avg upside
14 analysts
$27.00
233.29% Upside
 +22.5%
OKUR
OnKure Therapeutics
 Mar 16, 2026 BUY Buy
+428.3% avg upside
12 analysts
$27.00
502.63% Upside
 -21.0%
AUTL
Autolus Therapeutics
 Feb 13, 2026 BUY Strong Buy
+605.8% avg upside
16 analysts
$8.00
429.78% Upside
 +4.3%
HURA
TuHURA Biosciences
 Feb 03, 2026 BUY Strong Buy
+266.6% avg upside
8 analysts
$10.00
289.19% Upside
 +435.3%
PMVP
PMV Pharmaceuticals
 Nov 12, 2025 BUY Strong Buy
+1207.4% avg upside
12 analysts
$5.00
342.45% Upside
 -9.2%
ATRA
Atara Biotherapeutics
 Aug 19, 2025 HOLD Buy
+79.8% avg upside
18 analysts
 — -15.8%
APLM
Apollomics
 Sep 03, 2024 HOLD Strong Buy
+8.1% avg upside
3 analysts
 — -62.9%
EFTR
eFFECTOR Therapeutics
 Jul 16, 2024 HOLD Strong Buy
+66249899.9% avg upside
5 analysts
 — -99.6%
GTBP
GT Biopharma
 May 24, 2024 HOLD Strong Buy
+1942.8% avg upside
3 analysts
 — -21.5%
CLDI
Calidi Biotherapeutics
 Mar 21, 2024 BUY Strong Buy
+6314.1% avg upside
3 analysts
$20.00
11741.31% Upside
 -87.7%
ALP
Alpha Compute
 Jan 08, 2024 HOLD Strong Buy
+8018.9% avg upside
6 analysts
 — ·
NGNE
Neurogene
 Mar 21, 2023 HOLD Buy
+55.9% avg upside
23 analysts
 — +269.0%
IMA
ImageneBio
 Mar 17, 2023 BUY Strong Buy
+179.6% avg upside
12 analysts
$22.00
266.66% Upside
 -61.8%
CTMX
CytomX Therapeutics
 May 10, 2022 BUY Strong Buy
+269.4% avg upside
21 analysts
$11.00
272.83% Upside
 +2.2%
SE:ONCO
Oncopeptides AB
 Oct 22, 2021 SELL Hold
2 analysts
 — ·
NCNA
Nucana
 Mar 05, 2021 BUY Strong Buy
+559.7% avg upside
9 analysts
$10.00
423.64% Upside
 -78.2%
🔒 44 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Robert Burns — Frequently Asked Questions
How accurate are Robert Burns's stock ratings?
Based on the calls 13Foresight could measure, about 45% of Robert's ratings were profitable over a one-year hold, with an average return of -4.5% per rating, or -10.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Robert ranked on 13Foresight?
Robert Burns is currently ranked #2385 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Robert cover?
Robert most recently has ratings on KPTI, COGT, ELTX, CRBU, NRIX, TNGX, FATE, CGEM, ADCT, ORIC, RADX, AKTS and 37 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.